KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash from Investing Activities: 2010-2024

Historic Cash from Investing Activities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to -$189.9 million.

  • Supernus Pharmaceuticals' Cash from Investing Activities rose 163.25% to $48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.8 million, marking a year-over-year increase of 117.59%. This contributed to the annual value of -$189.9 million for FY2024, which is 170.65% down from last year.
  • According to the latest figures from FY2024, Supernus Pharmaceuticals' Cash from Investing Activities is -$189.9 million, which was down 170.65% from $268.7 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Cash from Investing Activities ranged from a high of $268.7 million in FY2023 and a low of -$216.7 million during FY2022.
  • In the last 3 years, Supernus Pharmaceuticals' Cash from Investing Activities had a median value of -$189.9 million in 2024 and averaged -$45.9 million.
  • In the last 5 years, Supernus Pharmaceuticals' Cash from Investing Activities skyrocketed by 224.03% in 2023 and then crashed by 170.65% in 2024.
  • MRY analysis of 5 years shows Supernus Pharmaceuticals' Cash from Investing Activities stood at -$34.7 million in 2020, then plummeted by 136.07% to -$81.9 million in 2021, then plummeted by 164.50% to -$216.7 million in 2022, then skyrocketed by 224.03% to $268.7 million in 2023, then crashed by 170.65% to -$189.9 million in 2024.
  • Its last three reported values are -$189.9 million in FY2024, $268.7 million for FY2023, and -$216.7 million during FY2022.